

**TABLE 2** Complete remission and mortality rate in different characteristics of total pediatric AML patient.

| Characteristics                    | CR(N=235)      | <i>P</i> value | Mortality(N=122) | <i>P</i> value |
|------------------------------------|----------------|----------------|------------------|----------------|
| <b>WBC count, n/N, (%)</b>         |                |                |                  |                |
| ≥50×10 <sup>9</sup> /L             | 61/81(75.31)   | 0.759          | 41/81(50.62)     | 0.020          |
| <50×10 <sup>9</sup> /L             | 174/226(76.99) |                | 81/226(35.84)    |                |
| <b>Gender, n/N, (%)</b>            |                |                |                  |                |
| Male                               | 129/175(73.71) | 0.177          | 79/175(45.14)    | 0.026          |
| Female                             | 106/132(80.30) |                | 43/132(32.58)    |                |
| <b>Age, n/N, (%)</b>               |                |                |                  |                |
| ≤3 years                           | 38/61(62.30)   | 0.003          | 30/61(49.18)     | 0.092          |
| >3 year                            | 197/246(80.08) |                | 92/246(37.40)    |                |
| <b>Cytogenetics, n/N, (%)</b>      |                |                |                  |                |
| Adverse                            | 48(64.86)      | 0.006          | 40(54.05)        | 0.004          |
| Favorable/intermediate             | 187(80.26)     |                | 82(35.19)        |                |
| <b>Molecular biology, n/N, (%)</b> |                |                |                  |                |
| CBF-AML positive                   | 116/127(91.34) | <0.001         | 34/127(26.77)    | <0.001         |
| CBF-AML negative                   | 119/180(66.11) |                | 88/180(48.89)    |                |
| FLT3-ITD positive                  | 14/25(56.00)   | 0.011          | 11/25(44.00)     | 0.650          |
| FLT3-ITD negative                  | 221/282(78.37) |                | 111/282(39.36)   |                |
| KMT2A-R positive                   | 14/24(58.33)   | 0.280          | 14/24(58.33)     | 0.053          |
| KMT2A-R negative                   | 221/283(78.09) |                | 108/283(38.16)   |                |
| CEBPA double mutation positive     | 10/11(90.91)   | 0.468          | 2/11(18.18)      | 0.210          |
| CEBPA double mutation negative     | 225/296(76.01) |                | 120/296(40.54)   |                |
| NPM1 positive                      | 4/4(100)       | 0.576          | 1/4(25.0)        | 1.000          |
| NPM1 negative                      | 231/303(76.24) |                | 121/303(39.93)   |                |

Abbreviations: WBC: white blood cell, CR: complete remission, n/N: positive/total, CBF-AML: core binding factor acute myeloid leukemia, *FLT3-ITD*: FMS-like tyrosine kinase 3-internal tandem duplication, *KMT2A-R*: lysine methyltransferase 2A rearrangements, *CEBPA*: CCAAT enhancer binding protein alpha, *NPM1*: nucleophosmin 1.

Cytogenetic risk was grouped according to 2017 ELN: Favorable: t(8;21)(q22; q22.1), inv(16)(p13.1q22) or t(16;16)(p13.1; q22). Intermediate: t(9;11)(p21.3;q23.3), cytogenetic abnormalities not classified as favorable or adverse. Adverse: t(6;9)(p23;q34.1), t(v;11q23.3), t(9;22)(q34.1;q11.2), inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2), -5 or del(5q), -7, -17/abn(17p), complex karyotype ,or monosomal karyotypell.